Abstract: The present invention provides an integrase inhibitor. The inventors have found the following compound of formula (I) possessing an integrase inhibitory activity. (wherein, RC and RD taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxyl, mercapto or amino; Z is O, S or NH; RA is a group shown by (wherein, C ring is N-containing aromatic heterocycle) or the like).

Abstract: The present invention provides an integrase inhibitor. The inventors have found the following compound of formula (I) possessing an integrase inhibitory activity. (wherein, RC and RD taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxyl, mercapto or amino; Z is O, S or NH; RA is a group shown by (wherein, C ring is N-containing aromatic heterocycle) or the like).

Abstract: The present invention provides an integrase inhibitor. The inventors have found the following compound of formula (I) possessing an integrase inhibitory activity. (wherein, RC and RD taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxyl, mercapto or amino; Z is O, S or NH; RA is a group shown by (wherein, C ring is N-containing aromatic heterocycle) or the like).

Abstract: The present invention provides an amine salt of a lignan compound, i.e., [1-O-[4-(3,4-dimethoxyphenyl)-2-(3-ethylpentanoyl)-5,6,7-trimethoxy-3-(methoxycarbonyl)naphthalen-1-yl]-beta-D-glucopyranoside]uronic acid, which is useful as a medicament. The present invention also provides a method for purifying said lignan compound.

Abstract: The present invention provides an integrase inhibitor. The inventors have have found the following compound of formula (I) possessing an integrase inhibitory activity.

Abstract: The present invention provides a compound of the formula (I): 1

Abstract: The present invention provides a compound of the formula (I): 1

Abstract: The present invention provides an amine salt of a lignan compound, i.e., [1-O-[4-(3,4-dimethoxyphenyl)-2-(3- ethylpentanoyl)-5,6,7-trimethoxy-3- (methoxycarbonyl)naphthalen-1-yl]-beta-D- glucopyranoside]uronic acid, which is useful as a medicament. The present invention also provides a method for purifying said lignan compound.

Abstract: An anti-hyperlipemic agent which has a potent activity of reducing LDL and VLDL cholesterols, which are thought to be a risk factor for arteriosclerosis among total blood cholesterols, and which is excellent in the antioxidant activity on LDL, is provided. Additionally, a compound and a pharmaceutically acceptable salt thereof are disclosed, which is represented by Formula (I): ##STR1## ?wherein R.sup.1 is a lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl group which is optionally substituted; R.sup.2 is a group represented by the formula: --COOR' (wherein R' is a lower alkyl or aralkyl which is optionally substituted), lower alkyl or halogenated lower alkyl; or R.sup.1 and R.sup.2, together with adjacent carbonyl group, form a cyclohexanone ring represented by the formula: ##STR2## R.sup.3 is a phenyl group optionally being substituted, and, ring A is a benzene nucleus which is optionally substituted, or a heterocyclic ring containing S or O optionally being substituted!.

Abstract: An anti-hyperlipemic agent which has a potent activity of reducing LDL and VLDL cholesterols, which are thought to be a risk factor for arteriosclerosis among total blood cholesterols, and which is excellent in the antioxidant activity on LDL, is provided. Additionally, a compound and a pharmaceutically acceptable salt thereof are disclosed, which is represented by Formula (I): ##STR1## wherein R.sup.1 is a lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl group which is optionally substituted; R.sup.2 is a group represented by the formula: -COOR' (wherein R' is a lower alkyl or aralkyl which is optionally substituted), lower alkyl or halogenated lower alkyl; or R.sup.1 and R.sup.2, together with adjacent carbonyl group, form a cyclohexanone ring represented by the formula: ##STR2## R.sup.3 is a phenyl group optionally being substituted, and, ring A is a benzene nucleus which is optionally substituted, or a heterocyclic ring containing S or 0 optionally being substituted!.

Abstract: This invention relates to a process for preparation of the compounds of lignan series in a regioselective manner. This invention provide a process for preparing a compound of the formula (I):which process is characterized by that a lactone compound represented by the formula (II) is allowed to react with a compound of the formula: R.sup.7 Cl in the presence of a base, then the resulting compound is subjected to addition reaction with an acetylenic compound of the formula (III), then the resulting compound is reduced;in which R.sup.1 is alkyl, cycloalkyl, cycloalkyl lower alkyl, or aralkyl and the like; R.sup.2 and R.sup.3 each is lower alkoxy and the like; R.sup.4 is lower alkoxy or hydrogen; and R.sup.5 and R.sup.6 each is lower alkyl; and R.sup.7 is tri(lower alkyl)silyl.

Abstract: An anti-hyperlipemic agent which has a potent activity of reducing LDL and VLDL cholesterols, which are thought to be a risk factor for arteriosclerosis among total blood cholesterols, and which is excellent in the antioxidant activity on LDL, is provided. Additionally, a compound and a pharmaceutically acceptable salt thereof are disclosed, which is represented by Formula (I): ##STR1## [wherein R.sup.1 is a lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl group which is optionally substituted; R.sup.2 is a group represented by the formula: --COOR' (wherein R' is a lower alkyl or aralkyl which is optionally substituted), lower alkyl or halogenated lower alkyl; or R.sup.1 and R.sup.2, together with adjacent carbonyl group, form a cyclohexanone ring represented by the formula: ##STR2## R.sup.3 is a phenyl group optionally being substituted, and, ring A is a benzene nucleus which is optionally substituted, or a heterocyclic ring containing S or O optionally being substituted].

Abstract: An anti-hyperlipemic agent which has a potent activity of reducing LDL and VLDL cholesterols, which are thought to be a risk factor for arteriosclerosis among total blood cholesterols, and which is excellent in the antioxidant activity on LDL, is provided. Additionally, a compound and a pharmaceutically acceptable salt thereof are disclosed, which is represented by Formula (I): ##STR1## [wherein R.sup.1 is a power alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl group which is optionally substituted; R.sup.2 is a group represented by the formula: --COOR' (wherein R' is a lower alkyl or aralkyl which is optionally substituted), lower alkyl or halogenated lower alkyl; or R.sup.1 and R.sup.2, together with adjacent carbonyl group, form a cyclohexanone ring represented by the formula: ##STR2## R.sup.3 is a phenyl group optionally being substituted, and, ring A is a benzene nucleus which is optionally substituted, or a heterocyclic ring containing S or O optionally being substituted].

Abstract: Benzodioxane prostacyclin analogs represented by the formula: ##STR1## wherein R.sub.1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or phenoxyalkyl; R.sub.2 is hydrogen, lower alkyl, or aralkyl; R.sub.3 is hydrogen or a protecting group; A is ethylene or vinylene; and the wavy line indicates .alpha. or .beta. configuration or their mixture; or a salt thereof having an antiulcer activity and platelet aggregation inhibitory activity.

Abstract: Prostacyclin (PGI.sub.2) analogues represented by the formula: ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 is lower alkenyl; R.sub.3 and R.sub.4 each is hydrogen or hydroxy-protecting group; R.sub.5 is straight or branched alkyl which may be substituted with heterocycle, straight or branched alkynyl, or cycloalkyl; the wavy line indicates R- or S-configuration, or their mixture; or a salt thereof being used as antithrombotic and antiulcer drugs.

Abstract: Prostacyclin (PGI.sub.2) analogues represented by the formula: ##STR1## wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 is alkynyl; R.sub.3 and R.sub.4 each is hydrogen; R.sub.5 is straight or branched alkyl which may be substituted with heterocycle, straight or branched alkynyl, or cycloalkyl; the wavy line indicates R- or S-configuration, or their mixture; or a salt thereof being used as antithrombotic and antiulcer drugs.